This article is more than 5 years old. Information may no longer be current.
FDA approves Prolensa for pain, inflammation after cataract surgery
Click Here to Manage Email Alerts
The U.S. Food and Drug Administration approved Bausch + Lomb’s new drug application for bromfenac ophthalmic solution, according to a company news release.
Prolensa (bromfenac ophthalmic solution 0.07%), a once-daily topical NSAID, is designed for the treatment of ocular inflammation and reduction of ocular pain after cataract surgery.
In two randomized, double-masked, vehicle-controlled trials, Prolensa demonstrated superiority to vehicle in the treatment of pain and inflammation after cataract surgery.
Complete clearance of inflammation by 15 days postop was seen in 46% of patients who received Prolensa compared with 20% of patients who received vehicle. In addition, 78.8% of patients who received Prolensa were pain free at day 1 postop, compared with 49.5% of patients who received vehicle.
The most common adverse reactions, which affected 3% to 8% of patients, were anterior chamber inflammation, foreign body sensation, eye pain, photophobia and blurred vision.
Prolensa will be available in 1.6 mL and 3 mL bottle sizes. The solution will not require shaking to deliver a consistent dosage, according to the release. The recommended dosage is one drop in the affected eye from the day before surgery to 14 days after surgery.